New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease

doi:10.1007/s11515-015-1360-4

Front. Biol.

2015, Vol. 10

Issue (3) : 230-238 https://doi.org/10.1007/s11515-015-1360-4

REVIEW

New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease

Young-Cho Kim¹,Stephanie L. Alberico¹,Eric Emmons¹,Nandakumar S. Narayanan^1,^2,^*(

)

1. Department of Neurology, University of Iowa, Iowa City, IA 52242, USA
2. Aging Mind and Brain Initiative, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA

Download: PDF(314 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

The neurotransmitter dopamine acts via two major classes of receptors, D1-type and D2-type. D1 receptors are highly expressed in the striatum and can also be found in the cerebral cortex. Here we review the role of D1 dopamine signaling in two major domains: L-DOPA-induced dyskinesias in Parkinson’s disease and cognition in neuropsychiatric disorders. While there are many drugs targeting D2-type receptors, there are no drugs that specifically target D1 receptors. It has been difficult to use selective D1-receptor agonists for clinical applications due to issues with bioavailability, binding affinity, pharmacological kinetics, and side effects. We propose potential therapies that selectively modulate D1 dopamine signaling by targeting second messengers downstream of D1 receptors, allosteric modulators, or by making targeted modifications to D1-receptor machinery. The development of therapies specific to D1-receptor signaling could be a new frontier in the treatment of neurological and psychiatric disorders.

Keywords cognition D1DR dopamine D1 receptor dyskinesia

Corresponding Author(s): Nandakumar S. Narayanan

Just Accepted Date: 17 April 2015 Online First Date: 14 May 2015 Issue Date: 23 June 2015

Cite this article:

Stephanie L. Alberico,Eric Emmons,Young-Cho Kim, et al. New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease[J]. Front. Biol., 2015, 10(3): 230-238.

URL:

https://academic.hep.com.cn/fib/EN/10.1007/s11515-015-1360-4
https://academic.hep.com.cn/fib/EN/Y2015/V10/I3/230

Fig.1 Schematic diagram shows projections of midbrain dopaminergic projections (ventral tegmental area or substantia nigra) to the frontal cortex and striatum and intracellular signaling pathway in a D1 receptor synapse. Midbrain dopaminergic neurons (red) project to both glutamatergic pyramidal neurons (purple) and GABAergic interneurons (gray) in prefrontal cortex. Some midbrain dopaminergic neurons project to medium spiny neurons in the striatum that express either D1 dopamine receptors (blue) or D2 dopamine receptors (green). Dopamine synthesis in dopaminergic neurons requires two key proteins, tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC), which are target molecules for dopaminergic degenerating diseases (PD). D1DRs in post-synaptic neurons are coupled with G-proteins. Activation of D1DRs stimulates adenylate cyclase (AC) which results in increased cAMP levels. Increasing PKA activity with cAMP changes subsequently induces phosphorylation of DARPP-32.

1	Ariano M A, Sibley D R (1994). Dopamine receptor distribution in the rat CNS: elucidation using anti-peptide antisera directed against D1A and D3 subtypes. Brain Res, 649(1–2): 95–110 https://doi.org/10.1016/0006-8993(94)91052-9 pmid: 7953659
2	Arnsten A F, Cai J X, Murphy B L, Goldman-Rakic P S (1994). Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl), 116(2): 143–151 https://doi.org/10.1007/BF02245056 pmid: 7862943
3	Aubert I, Guigoni C, H?kansson K, Li Q, Dovero S, Barthe N, Bioulac B H, Gross C E, Fisone G, Bloch B, Bezard E (2005). Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol, 57(1): 17–26 https://doi.org/10.1002/ana.20296 pmid: 15514976
4	Bartus R T, Baumann T L, Siffert J, Herzog C D, Alterman R, Boulis N, Turner D A, Stacy M, Lang A E, Lozano A M, Olanow C W (2013). Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology, 80(18): 1698–1701 https://doi.org/10.1212/WNL.0b013e3182904faa pmid: 23576625
5	Bergson C, Mrzljak L, Smiley J F, Pappy M, Levenson R, Goldman-Rakic P S (1995). Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci, 15(12): 7821–7836 pmid: 8613722
6	Berthet A, Porras G, Doudnikoff E, Stark H, Cador M, Bezard E, Bloch B (2009). Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci, 29(15): 4829–4835 https://doi.org/10.1523/JNEUROSCI.5884-08.2009 pmid: 19369551
7	Blanchet P J, Konitsiotis S, Chase T N (1998). Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord, 13(5): 798–802 https://doi.org/10.1002/mds.870130507 pmid: 9756148
8	Boyden E S, Zhang F, Bamberg E, Nagel G, Deisseroth K (2005). Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci, 8(9): 1263–1268 https://doi.org/10.1038/nn1525 pmid: 16116447
9	Calabresi P, Di Filippo M, Ghiglieri V, Picconi B (2008). Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord, 23(Suppl 3): S570–S579 https://doi.org/10.1002/mds.22019 pmid: 18781674
10	Carter M E, de Lecea L (2011). Optogenetic investigation of neural circuits in vivo. Trends Mol Med, 17(4): 197–206 https://doi.org/10.1016/j.molmed.2010.12.005 pmid: 21353638
11	Castner S A, Goldman-Rakic P S (2004). Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci, 24(6): 1446–1450 https://doi.org/10.1523/JNEUROSCI.3987-03.2004 pmid: 14960617
12	Castner S A, Williams G V, Goldman-Rakic P S (2000). Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science, 287(5460): 2020–2022 https://doi.org/10.1126/science.287.5460.2020 pmid: 10720329
13	Cavanagh J F, Frank M J (2014). Frontal theta as a mechanism for cognitive control. Trends Cogn Sci, 18(8): 414–421 https://doi.org/10.1016/j.tics.2014.04.012 pmid: 24835663
14	Charifson P S, Bowen J P, Wyrick S D, Hoffman A J, Cory M, McPhail A T, Mailman R B (1989). Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. J Med Chem, 32(9): 2050–2058 https://doi.org/10.1021/jm00129a006 pmid: 2527994
15	Cools R, Barker R A, Sahakian B J, Robbins T W (2001). Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex, 11(12): 1136–1143 https://doi.org/10.1093/cercor/11.12.1136 pmid: 11709484
16	Cools R, D’Esposito M (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry, 69(12): e113–e125 https://doi.org/10.1016/j.biopsych.2011.03.028 pmid: 21531388
17	Cools R, Stefanova E, Barker R A, Robbins T W, Owen A M (2002). Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain, 125(Pt 3): 584–594 https://doi.org/10.1093/brain/awf052 pmid: 11872615
18	Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo G A (2009). Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia, 47(5): 1374–1381 https://doi.org/10.1016/j.neuropsychologia.2009.01.039 pmid: 19428401
19	Creese I, Burt D R, Snyder S H (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192(4238): 481–483 3854 https://doi.org/10.1126/science.3854 pmid: 3854
20	Cui G, Jun S B, Jin X, Pham M D, Vogel S S, Lovinger D M, Costa R M (2013). Concurrent activation of striatal direct and indirect pathways during action initiation. Nature, 494(7436): 238–242 https://doi.org/10.1038/nature11846 pmid: 23354054
21	Darmopil S, Martín A B, De Diego I R, Ares S, Moratalla R (2009). Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry, 66(6): 603–613 https://doi.org/10.1016/j.biopsych.2009.04.025 pmid: 19520364
22	Farrell M S, Pei Y, Wan Y, Yadav P N, Daigle T L, Urban D J, Lee H M, Sciaky N, Simmons A, Nonneman R J, Huang X P, Hufeisen S J, Guettier J M, Moy S S, Wess J, Caron M G, Calakos N, Roth B L (2013). A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology, 38(5): 854–862 https://doi.org/10.1038/npp.2012.251 pmid: 23303063
23	Fawzi A B, Macdonald D, Benbow L L, Smith-Torhan A, Zhang H, Weig B C, Ho G, Tulshian D, Linder M E, Graziano M P (2001). SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol Pharmacol, 59(1): 30–37 pmid: 11125021
24	Feenstra M G, Teske G, Botterblom M H, De Bruin J P (1999). Dopamine and noradrenaline release in the prefrontal cortex of rats during classical aversive and appetitive conditioning to a contextual stimulus: interference by novelty effects. Neurosci Lett, 272(3): 179–182 https://doi.org/10.1016/S0304-3940(99)00601-1 pmid: 10505610
25	Feenstra M G, Vogel M, Botterblom M H, Joosten R N, de Bruin J P (2001). Dopamine and noradrenaline efflux in the rat prefrontal cortex after classical aversive conditioning to an auditory cue. Eur J Neurosci, 13(5): 1051–1054 https://doi.org/10.1046/j.0953-816x.2001.01471.x pmid: 11264679
26	Fienberg A A, Hiroi N, Mermelstein P G, Song W, Snyder G L, Nishi A, Cheramy A, O’Callaghan J P, Miller D B, Cole D G, Corbett R, Haile C N, Cooper D C, Onn S P, Grace A A, Ouimet C C, White F J, Hyman S E, Surmeier D J, Girault J, Nestler E J, Greengard P (1998). DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science, 281(5378): 838–842 https://doi.org/10.1126/science.281.5378.838 pmid: 9694658
27	Flores-Hernández J, Cepeda C, Hernández-Echeagaray E, Calvert C R, Jokel E S, Fienberg A A, Greengard P, Levine M S (2002). Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol, 88(6): 3010–3020 https://doi.org/10.1152/jn.00361.2002 pmid: 12466426
28	Frederick A L, Yano H, Trifilieff P, Vishwasrao H D, Biezonski D, Mészáros J, Urizar E, Sibley D R, Kellendonk C, Sonntag K C, Graham D L, Colbran R J, Stanwood G D, Javitch J A (2015). Evidence against dopamine D1/D2 receptor heteromers. Mol Psychiatry, doi: 10.1038/mp.2014.166 pmid: 25560761
29	Friedman J H, Lannon M C (1989). Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology, 39(9): 1219–1221 https://doi.org/10.1212/WNL.39.9.1219 pmid: 2771073
30	Fuster J (2008) The Prefrontal Cortex, 4th Edition. Academic Press, New York, NY
31	Gangarossa G, Longueville S, De Bundel D, Perroy J, Hervé D, Girault J A, Valjent E (2012). Characterization of dopamine D1 and D2 receptor-expressing neurons in the mouse hippocampus. Hippocampus, 22(12): 2199–2207 https://doi.org/10.1002/hipo.22044 pmid: 22777829
32	Gerfen C R, Miyachi S, Paletzki R, Brown P (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci, 22(12): 5042–5054 pmid: 12077200
33	Goldman-Rakic P S (1998). The cortical dopamine system: role in memory and cognition. Adv Pharmacol, 42: 707–711 https://doi.org/10.1016/S1054-3589(08)60846-7 pmid: 9327997
34	Goldman-Rakic P S, Castner S A, Svensson T H, Siever L J, Williams G V (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl), 174(1): 3–16 https://doi.org/10.1007/s00213-004-1793-y pmid: 15118803
35	Goldman-Rakic P S, Muly E C 3rd, Williams G V (2000). D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev, 31(2–3): 295–301 https://doi.org/10.1016/S0165-0173(99)00045-4 pmid: 10719156
36	Grace A A, Floresco S B, Goto Y, Lodge D J (2007). Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci, 30(5): 220–227 https://doi.org/10.1016/j.tins.2007.03.003 pmid: 17400299
37	Green M F, Harvey P D (2014). Cognition in schizophrenia: Past, present, and future. Schizophr Res Cogn, 1(1): e1–e9 https://doi.org/10.1016/j.scog.2014.02.001 pmid: 25254156
38	Guttman M, Seeman P (1985). L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson’s diseased striatum. J Neural Transm, 64(2): 93–103 https://doi.org/10.1007/BF01245971 pmid: 2934514
39	Ha C M, Park D, Han J K, Jang J I, Park J Y, Hwang E M, Seok H, Chang S (2012). Calcyon forms a novel ternary complex with dopamine D1 receptor through PSD-95 protein and plays a role in dopamine receptor internalization. J Biol Chem, 287(38): 31813–31822 https://doi.org/10.1074/jbc.M112.370601 pmid: 22843680
40	Hagger C, Buckley P, Kenny J T, Friedman L, Ubogy D, Meltzer H Y (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry, 34(10): 702–712 https://doi.org/10.1016/0006-3223(93)90043-D pmid: 8292674
41	Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994). Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology, 11(4): 245–256 https://doi.org/10.1038/sj.npp.1380111 pmid: 7531978
42	Hanrieder J, Ljungdahl A, F?lth M, Mammo SE, Bergquist J, Andersson M (2011) L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics MCP 10:M111.009308 https://doi.org/10.1074/mcp.M111.009308
43	Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier D J (2000). D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J Neurosci, 20(24): 8987–8995 pmid: 11124974
44	Hoare S R, Coldwell M C, Armstrong D, Strange P G (2000). Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol, 130(5): 1045–1059 https://doi.org/10.1038/sj.bjp.0703370 pmid: 10882389
45	Hoffman B, Cho S J, Zheng W, Wyrick S, Nichols D E, Mailman R B, Tropsha A (1999). Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. J Med Chem, 42(17): 3217–3226 https://doi.org/10.1021/jm980415j pmid: 10464009
46	Jenner P (2008). Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci, 9(9): 665–677 https://doi.org/10.1038/nrn2471 pmid: 18714325
47	Karlsson P, Smith L, Farde L, H?rnryd C, Sedvall G, Wiesel F A (1995). Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl), 121(3): 309–316 https://doi.org/10.1007/BF02246068 pmid: 8584611
48	K?tzel D, Nicholson E, Schorge S, Walker M C, Kullmann D M (2014). Chemical-genetic attenuation of focal neocortical seizures. Nat Commun, 5: 3847 https://doi.org/10.1038/ncomms4847 pmid: 24866701
49	Kemppainen N, Ruottinen H, Nagren K, Rinne J O (2000). PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology, 55(2): 205–209 https://doi.org/10.1212/WNL.55.2.205 pmid: 10908891
50	Khor S P, Hsu A (2007). The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol, 2(3): 234–243 https://doi.org/10.2174/157488407781668802 pmid: 18690870
51	Klein C, Gordon J, Pollak L, Rabey J M (2003). Clozapine in Parkinson’s disease psychosis: 5-year follow-up review. Clin Neuropharmacol, 26(1): 8–11 https://doi.org/10.1097/00002826-200301000-00003 pmid: 12567158
52	Kravitz A V, Freeze B S, Parker P R L, Kay K, Thwin M T, Deisseroth K, Kreitzer A C (2010). Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature, 466(7306): 622–626 https://doi.org/10.1038/nature09159 pmid: 20613723
53	LaHoste G J, Henry B L, Marshall J F (2000). Dopamine D1 receptors synergize with D2, but not D3 or D4, receptors in the striatum without the involvement of action potentials. J Neurosci, 20(17): 6666–6671 pmid: 10964971
54	Land B B, Narayanan N S, Liu R J, Gianessi C A, Brayton C E, Grimaldi D M, Sarhan M, Guarnieri D J, Deisseroth K, Aghajanian G K, DiLeone R J (2014). Medial prefrontal D1 dopamine neurons control food intake. Nat Neurosci, 17(2): 248–253 https://doi.org/10.1038/nn.3625 pmid: 24441680
55	Lapish C C, Kroener S, Durstewitz D, Lavin A, Seamans J K (2007). The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology (Berl), 191(3): 609–625 https://doi.org/10.1007/s00213-006-0527-8 pmid: 17086392
56	Lee S P, Xie Z, Varghese G, Nguyen T, O’Dowd B F, George S R (2000). Oligomerization of dopamine and serotonin receptors. Neuropsychopharmacology, 23(4 Suppl): S32–S40 https://doi.org/10.1016/S0893-133X(00)00155-X pmid: 11008065
57	Lemberger T, Parlato R, Dassesse D, Westphal M, Casanova E, Turiault M, Tronche F, Schiffmann S N, Schütz G (2007). Expression of Cre recombinase in dopaminoceptive neurons. BMC Neurosci, 8(1): 4 https://doi.org/10.1186/1471-2202-8-4 pmid: 17201924
58	LeWitt P A, Rezai A R, Leehey M A, Ojemann S G, Flaherty A W, Eskandar E N, Kostyk S K, Thomas K, Sarkar A, Siddiqui M S, Tatter S B, Schwalb J M, Poston K L, Henderson J M, Kurlan R M, Richard I H, Van Meter L, Sapan C V, During M J, Kaplitt M G, Feigin A (2011). AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol, 10(4): 309–319 https://doi.org/10.1016/S1474-4422(11)70039-4 pmid: 21419704
59	Lidow M S, Goldman-Rakic P S, Gallager D W, Rakic P (1991). Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience, 40(3): 657–671 https://doi.org/10.1016/0306-4522(91)90003-7 pmid: 2062437
60	Mailman R B, Murthy V (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des, 16(5): 488–501 https://doi.org/10.2174/138161210790361461 pmid: 19909227
61	Mattila P M, R?ytt? M, L?nnberg P, Marjam?ki P, Helenius H, Rinne J O (2001). Choline acetytransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol, 102(2): 160–166 pmid: 11563631
62	Narayanan N S, Guarnieri D J, DiLeone R J (2010). Metabolic hormones, dopamine circuits, and feeding. Front Neuroendocrinol, 31(1): 104–112 https://doi.org/10.1016/j.yfrne.2009.10.004 pmid: 19836414
63	Narayanan N S, Land B B, Solder J E, Deisseroth K, DiLeone R J (2012). Prefrontal D1 dopamine signaling is required for temporal control. Proc Natl Acad Sci USA, 109(50): 20726–20731 https://doi.org/10.1073/pnas.1211258109 pmid: 23185016
64	Narayanan N S, Rodnitzky R L, Uc E Y (2013). Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev Neurosci, 24(3): 267–278 https://doi.org/10.1515/revneuro-2013-0004 pmid: 23729617
65	Neumeyer J L, Kula N S, Bergman J, Baldessarini R J (2003). Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol, 474(2–3): 137–140 https://doi.org/10.1016/S0014-2999(03)02008-9 pmid: 12921854
66	Parker K L, Alberico S L, Miller A D, Narayanan N S (2013a). Prefrontal D1 dopamine signaling is necessary for temporal expectation during reaction time performance. Neuroscience, 255: 246–254 https://doi.org/10.1016/j.neuroscience.2013.09.057 pmid: 24120554
67	Parker K L, Chen K H, Kingyon J R, Cavanagh J F, Narayanan N S (2014). D1-dependent 4 Hz oscillations and ramping activity in rodent medial frontal cortex during interval timing. J Neurosci, 34(50): 16774–16783 https://doi.org/10.1523/JNEUROSCI.2772-14.2014 pmid: 25505330
68	Parker K L, Lamichhane D, Caetano M S, Narayanan N S (2013b). Executive dysfunction in Parkinson’s disease and timing deficits. Front Integr Neurosci, 7: 75 https://doi.org/10.3389/fnint.2013.00075 pmid: 24198770
69	Perreault M L, Hasbi A, O’Dowd B F, George S R (2011). The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia. Front Neuroanat, 5: 31 https://doi.org/10.3389/fnana.2011.00031 pmid: 21747759
70	Phillips A G, Ahn S, Floresco S B (2004). Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci, 24(2): 547–553 https://doi.org/10.1523/JNEUROSCI.4653-03.2004 pmid: 14724255
71	Pifl C, Nanoff C, Schingnitz G, Schütz W, Hornykiewicz O (1992). Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson’s disease. J Neurochem, 58(6): 1997–2004 https://doi.org/10.1111/j.1471-4159.1992.tb10939.x pmid: 1349341
72	Pisani A, Shen J (2009). Levodopa-induced dyskinesia and striatal signaling pathways. Proc Natl Acad Sci USA, 106(9): 2973–2974 https://doi.org/10.1073/pnas.0900802106 pmid: 19251671
73	Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, Battistin L (1996). Reduced striatal dopamine receptors in Alzheimer’s disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology, 47(4): 1065–1068 https://doi.org/10.1212/WNL.47.4.1065 pmid: 8857746
74	Porras G, Berthet A, Dehay B, Li Q, Ladepeche L, Normand E, Dovero S, Martinez A, Doudnikoff E, Martin-Négrier M L, Chuan Q, Bloch B, Choquet D, Boué-Grabot E, Groc L, Bezard E (2012). PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest, 122(11): 3977–3989 https://doi.org/10.1172/JCI59426 pmid: 23041629
75	Rashid A J, So C H, Kong M M C, Furtak T, El-Ghundi M, Cheng R, O’Dowd B F, George S R (2007). D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA, 104(2): 654–659 https://doi.org/10.1073/pnas.0604049104 pmid: 17194762
76	Rektorová I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, Fiedler J, Klajblová H, Kulist’ák P, Ressner P, Svátová J, Urbánek K, Velísková J (2005). Cognitive performance in people with Parkinson’s disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol, 12(1): 9–15 https://doi.org/10.1111/j.1468-1331.2004.00966.x pmid: 15613141
77	Roberts B M, Seymour P A, Schmidt C J, Williams G V, Castner S A (2010). Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl), 210(3): 407–418 https://doi.org/10.1007/s00213-010-1840-9 pmid: 20401749
78	Rodnitzky R L, Narayanan N S (2014). Amantadine’s role in the treatment of levodopa-induced dyskinesia. Neurology, 82(4): 288–289 https://doi.org/10.1212/WNL.0000000000000068 pmid: 24371305
79	Rossetti Z L, Carboni S (2005). Noradrenaline and dopamine elevations in the rat prefrontal cortex in spatial working memory. J Neurosci, 25(9): 2322–2329 https://doi.org/10.1523/JNEUROSCI.3038-04.2005 pmid: 15745958
80	Santana N, Mengod G, Artigas F (2009). Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex, 19(4): 849–860 https://doi.org/10.1093/cercor/bhn134 pmid: 18689859
81	Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault J A, Hervé D, Greengard P, Fisone G (2007). Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci, 27(26): 6995–7005 https://doi.org/10.1523/JNEUROSCI.0852-07.2007 pmid: 17596448
82	Sawaguchi T, Goldman-Rakic P S (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science, 251(4996): 947–950 https://doi.org/10.1126/science.1825731 pmid: 1825731
83	Sawaguchi T, Goldman-Rakic P S (1994). The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol, 71(2): 515–528 pmid: 7909839
84	Schultz W (1997). Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol, 7(2): 191–197 https://doi.org/10.1016/S0959-4388(97)80007-4 pmid: 9142754
85	Schultz W (2001). Reward signaling by dopamine neurons. Neuroscientist, 7(4): 293–302 https://doi.org/10.1177/107385840100700406 pmid: 11488395
86	Seeman P (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1(2): 133–152 https://doi.org/10.1002/syn.890010203 pmid: 2905529
87	Seeman P, Chau-Wong M, Tedesco J, Wong K (1975). Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA, 72(11): 4376–4380 https://doi.org/10.1073/pnas.72.11.4376 pmid: 1060115
88	Sesack S R, Carr D B, Omelchenko N, Pinto A (2003). Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci, 1003(1): 36–52 https://doi.org/10.1196/annals.1300.066 pmid: 14684434
89	Shuen J A, Chen M, Gloss B, Calakos N (2008). Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci, 28(11): 2681–2685 https://doi.org/10.1523/JNEUROSCI.5492-07.2008 pmid: 18337395
90	Soriano A, Vendrell M, Gonzalez S, Mallol J, Albericio F, Royo M, Lluís C, Canela E I, Franco R, Cortés A, Casadó V (2010). A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors. J Pharmacol Exp Ther, 332(3): 876–885 https://doi.org/10.1124/jpet.109.158824 pmid: 20026675
91	Sun P, Wang J, Gu W, Cheng W, Jin G Z, Friedman E, Zheng J, Zhen X (2009). PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation. Cell Res, 19(5): 612–624 https://doi.org/10.1038/cr.2009.30 pmid: 19274064
92	Takahashi H, Kato M, Takano H, Arakawa R, Okumura M, Otsuka T, Kodaka F, Hayashi M, Okubo Y, Ito H, Suhara T (2008). Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. J Neurosci, 28(46): 12032–12038 https://doi.org/10.1523/JNEUROSCI.3446-08.2008 pmid: 19005068
93	Taylor J L, Bishop C, Walker P D (2005). Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav, 81(4): 887–893 https://doi.org/10.1016/j.pbb.2005.06.013 pmid: 16023708
94	Taymans J M, Kia H K, Groenewegen H J, Leysen J E, Langlois X (2005). Bilateral control of brain activity by dopamine D1 receptors: evidence from induction patterns of regulator of G protein signaling 2 and c-fos mRNA in D1-challenged hemiparkinsonian rats. Neuroscience, 134(2): 643–656 https://doi.org/10.1016/j.neuroscience.2005.04.047 pmid: 15964700
95	Ungless M A, Magill P J, Bolam J P (2004). Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science, 303(5666): 2040–2042 https://doi.org/10.1126/science.1093360 pmid: 15044807
96	Vijayraghavan S, Wang M, Birnbaum S G, Williams G V, Arnsten A F T (2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci, 10(3): 376–384 https://doi.org/10.1038/nn1846 pmid: 17277774
97	Watanabe M, Kodama T, Hikosaka K (1997). Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol, 78(5): 2795–2798 pmid: 9356427
98	Westin J E, Vercammen L, Strome E M, Konradi C, Cenci M A (2007). Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry, 62(7): 800–810 https://doi.org/10.1016/j.biopsych.2006.11.032 pmid: 17662258
99	Wilkinson L S, Humby T, Killcross A S, Torres E M, Everitt B J, Robbins T W (1998). Dissociations in dopamine release in medial prefrontal cortex and ventral striatum during the acquisition and extinction of classical aversive conditioning in the rat. Eur J Neurosci, 10(3): 1019–1026 https://doi.org/10.1046/j.1460-9568.1998.00119.x pmid: 9753169
100	Williams G V, Goldman-Rakic P S (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376(6541): 572–575 https://doi.org/10.1038/376572a0 pmid: 7637804
101	Yoshioka M, Matsumoto M, Togashi H, Saito H (1996). Effect of conditioned fear stress on dopamine release in the rat prefrontal cortex. Neurosci Lett, 209(3): 201–203 https://doi.org/10.1016/0304-3940(96)12631-8 pmid: 8736645
102	Zahrt J, Taylor J R, Mathew R G, Arnsten A F T (1997). Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci, 17(21): 8528–8535 pmid: 9334425

[1]	Richard König,Bruno Benedetti,Peter Rotheneichner,Anna O′ Sullivan,Christina Kreutzer,Maria Belles,Juan Nacher,Thomas M. Weiger,Ludwig Aigner,Sébastien Couillard-Després. Distribution and fate of DCX/PSA-NCAM expressing cells in the adult mammalian cortex: A local reservoir for adult cortical neuroplasticity?[J]. Front. Biol., 2016, 11(3): 193-213.
[2]	Paul J. Lucassen,Charlotte A. Oomen. Stress, hippocampal neurogenesis and cognition: functional correlations[J]. Front. Biol., 2016, 11(3): 182-192.
[3]	Afsar U. AHMED. An overview of inflammation: mechanism and consequences[J]. Front Biol, 2011, 6(4): 274-281.
[4]	LIU Xiang, WANG Yifei. A modified resonant recognition model to predict protein-protein interaction[J]. Front. Biol., 2007, 2(3): 268-271.

Viewed

Full text

Abstract

Cited

Shared

Discussed